Lizbeth Del Toro-Mejias

Ms. Lizbeth Del Toro-Mejias

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2022 in International Journal of Drug Policy
Verified
Journal Article
Closed access
TSThomas J Stopka
Thomas J Stopka
RRRebecca E. Rottapel
Rebecca E. Rottapel
WFWarren J. Ferguson
Warren J. Ferguson
EPEkaterina Pivovarova
Ekaterina Pivovarova
LTLizbeth Del Toro-Mejias
Lizbeth Del Toro-Mejias
EEElizabeth A. Evans
Elizabeth A. Evans

1 January 2016 in Journal Of Health Care For The Poor and Underserved
Verified
Journal Article
Open access
PDF file
VCVivian Colón-López
Vivian Colón-López
LTLizbeth Del Toro-Mejias
Lizbeth Del Toro-Mejias
ACAlexandra Conde-Toro
Alexandra Conde-Toro
MSMichelle J. Serra-Rivera
Michelle J. Serra-Rivera
TMTania M. Martínez
Tania M. Martínez
HVHéctor Villanueva
Héctor Villanueva
Objective. The purpose of this study was to understand through a quantitative assessment, the views of HPV and HPV vaccination among parents of sons from a FQHC in PR. Methods. A self-administered questionnaire was given to a convenience sample of 200 parents of sons 9–17 years old. Results. Nearly 30% of the parents reported that their sons had initiated the HPV vaccine regimen. Health care provider recommendation was significantly associated with vaccine initiation. Among parents of unvaccinated sons, the main reason for not getting the HPV vaccine was they did not know that boys were allowed to get the vaccine. Conclusions. Future efforts should focus on multilevel interventions aimed to increase knowledge as well as other modified behavioral determinants in parents of young males about HPV and the vaccine. Capacity building efforts should be targeted also to increase health providers’ education and communication skills to promote HPV vaccination effectively.

30 August 2024 in Viruses
Verified
Journal Article
Open access
PDF file
EBElyse Bianchet
Elyse Bianchet
DGDavid de Gijsel
David de Gijsel
LTLizbeth Del Toro-Mejias
Lizbeth Del Toro-Mejias
TSThomas J Stopka
Thomas J Stopka
RHRandall Hoskinson
Randall Hoskinson
PFPeter D. Friedmann
Peter D. Friedmann
Hepatitis C virus (HCV) disproportionately affects people who inject drugs (PWID). Although HCV has become universally curable since the arrival of direct-acting antivirals, barriers exist to facilitating care and cure in this historically hard-to-reach population, including limited testing and healthcare services and healthcare stigma, issues that are compounded in rural areas. Telehealth is effective in increasing access to HCV care and cure, but innovative approaches of testing and care are required to fully address the need among rural PWID, which led to our study examining a mobile telehealth model for treating HCV. In this commentary, we discuss lessons learned delivering telehealth on a mobile unit, important factors for consideration when designing a mobile intervention, and we suggest an ideal model to increase access to HCV testing and treatment and other services for rural PWID.